Table 4.

Linear and Logistic Regression Analysis of Triglycerides and HDL Outcomes Associated With Urinary Phthalate Metabolites

OutcomeOdds RatioIncrement
Triglyceride (n=350)
 LMW Metabolites0.83 (0.62, 1.12)−0.04 (−0.10, +0.007)
 HMW Metabolites1.07 (0.81, 1.42)−0.008 (−0.06, +0.04)
 DEHP Metabolites0.91 (0.69, 1.19)−0.02 (−0.07, +0.03)
 DIDP Metabolites1.01 (0.76, 1.36)−0.01 (−0.06, +0.04)
 DINP Metabolites1.19 (0.97, 1.47)+0.005 (−0.03, +0.04)
HDL (n=1186)
 LMW Metabolites1.17 (0.81, 1.71)+0.46 (−0.57, +1.50)
 HMW Metabolites0.93 (0.66, 1.32)+0.98 (−0.25, +2.20)
 DEHP Metabolites0.89 (0.58, 1.36)+1.20 (−0.17, +2.58)
 DIDP Metabolites0.97 (0.77, 1.23)−0.11 (−1.56, +1.33)
 DINP Metabolites0.89 (0.74, 1.05)+0.47 (−0.46, +1.40)
  • Increases are per log unit in urinary LMW/HMW/DEHP/DINP/DIDP metabolite concentration. See methods for calculation. Models control for sex, caloric intake, physical activity, poverty–income ratio, serum cotinine, urinary creatinine, BMI category, race/ethnicity, and age categories. Results using weighted modeling are presented here for HDL outcome; triglyceride outcome results are presented unweighted (see methods). BMI indicates body mass index; DEHP indicates di-2-ethylhexylphthalate; DIDP, di-isodecyl phthalate; DINP, di-isononyl phthalate; HDL, high-density lipoproteins; HMW, low-molecular weight; and LMW, low-molecular weight.